Windlas BiotechNSE:WINDLAS -1.56%91 PS Ratio is 2.02 as of Jul. 07, 2026, which is 12% above its 10-year median of 1.80. GuruFocus rates NSE:WINDLAS with a GF Score™ of 91/100 and a GF Value™ of ₹936.41 (Fairly Valued). The stock has 1 warning sign investors should review. Among 951 Drug Manufacturers companies, Windlas Biotech ranks better than 53.63% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Windlas Biotech's share price is ₹858.30.
Windlas Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹425.41. Hence, Windlas Biotech's PS Ratio for today is 2.02.
The historical rank and industry rank for Windlas Biotech's PS Ratio or its related term are showing as below:
NSE:WINDLAS'
s PS Ratio Range Over the Past 10 Years
Min: 0.95 Med: 1.8 Max: 3.45
Current: 2.02
During the past 8 years, Windlas Biotech's highest PS Ratio was 3.45. The lowest was 0.95. And the median was 1.80.
NSE:WINDLAS's PS Ratio is ranked better than 53.63% of 951
companies
in the Drug Manufacturers industry
Industry Median: 2.28
vs NSE:WINDLAS: 2.02
During the past 12 months, the average Revenue per Share Growth Rate of Windlas Biotech was 17.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 21.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 23.70% per year.
During the past 8 years, Windlas Biotech's highest 3-Year average Revenue per Share Growth Rate was 32.00% per year. The lowest was 16.10% per year. And the median was 17.30% per year.
Back to Basics: PS Ratio
Windlas Biotech (NSE:WINDLAS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Windlas Biotech PS Ratio Related Terms
Windlas Biotech PS Ratio Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's PS Ratio distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Windlas Biotech's Share Price of today is ₹858.30. Windlas Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹425.41.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Windlas Biotech (NSE:WINDLAS) has a PS Ratio of 2.02 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Windlas Biotech and its competitors. This is 12% above median its historical median of 1.80. Over the past decade, Windlas Biotech's PS Ratio has ranged from 0.95 to 3.45. According to the industry distribution chart, Windlas Biotech ranks #441 out of 951 companies in the Drug Manufacturers industry, placing it in the top 46.4%.
Is Windlas Biotech's PS Ratio too high?
Windlas Biotech's current PS Ratio of 2.02 is 12% above median its 10-year median of 1.80. Over the past 10 years, this metric has ranged from a low of 0.95 to a high of 3.45. The Drug Manufacturers industry median PS Ratio is 2.28. Windlas Biotech's value of 2.02 is 11.4% below this industry median. Based on the distribution chart, Windlas Biotech ranks #441 out of 951 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #441 out of 951 companies for PS Ratio. This puts Windlas Biotech in the upper half of its industry. The industry median PS Ratio is 2.28. Windlas Biotech's value of 2.02 is 11.4% below this benchmark. Historically, Windlas Biotech's own PS Ratio has ranged from 0.95 to 3.45 over the past decade. While the company's 10-year median is 1.80 vs. the industry median of 2.28, Windlas Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.28, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current PS Ratio of 2.02 is 11.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current PS Ratio is 2.02, which is 12% above median its own 10-year median of 1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.41, compared to a current price of ₹858.30 — trading 8.3% below its estimated fair value. The current PS Ratio is 2.02, which is 12% above median its 10-year median of 1.80 and 11.4% below the Drug Manufacturers industry median of 2.28. Windlas Biotech's overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current PS Ratio is 2.02 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹858.30 is trading 8.3% below its estimated GF Value™ of ₹936.41.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
PS Ratio: 2.02 (12% above median its 10-year median of 1.80)
GF Value™: ₹936.41 vs. price of ₹858.30 (8.3% below fair value)
Industry Position: 11.4% below the Drug Manufacturers median (#441 of 951)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
91GF Score
Get the complete analysis for NSE:WINDLAS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
